Indo-Bangla PharmaceuticalsDHA:IBP +5.14%32 Receivables Turnover is 0.00 as of . 20. GuruFocus rates DHA:IBP with a GF Score™ of 32/100. Among 947 Drug Manufacturers companies, Indo-Bangla Pharmaceuticals ranks worse than 105596.52% on this metric.
The Receivables Turnover ratio measures the number of times a company collects its average accounts receivable balance. It is calculated as Revenue divided by average Accounts Receivable. An efficient company has a higher accounts receivable turnover ratio while an inefficient company has a lower ratio. Indo-Bangla Pharmaceuticals's Revenue for the
six
months ended in . 20 was BDT0.00 Mil. Indo-Bangla Pharmaceuticals's average Accounts Receivable for the
six
months ended in . 20 was BDT0.00 Mil.
An efficient company has a higher accounts receivable turnover ratio while an inefficient company has a lower ratio. This metric is commonly used to compare companies within the same industry to check whether they are on par with their competitors.
Indo-Bangla Pharmaceuticals Receivables Turnover Related Terms
Indo-Bangla Pharmaceuticals Receivables Turnover Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Drug Manufacturers - Specialty & Generic subindustry, Indo-Bangla Pharmaceuticals's Receivables Turnover, along with its competitors' market caps and Receivables Turnover data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Indo-Bangla Pharmaceuticals Receivables Turnover vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Indo-Bangla Pharmaceuticals's Receivables Turnover distribution charts can be found below:
* The bar in red indicates where Indo-Bangla Pharmaceuticals's Receivables Turnover falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Indo-Bangla Pharmaceuticals (DHA:IBP) has a Receivables Turnover of 0.00 as of . 20. The accounts receivables turnover ratio measures the number of times a company collects its average accounts receivable balance. It is calculated as Revenue divided by Average Accounts Receivable. View historical data on Indo-Bangla Pharmaceuticals and its competitors. According to the industry distribution chart, Indo-Bangla Pharmaceuticals ranks #999999 out of 947 companies in the Drug Manufacturers industry.
Is Indo-Bangla Pharmaceuticals' Receivables Turnover too high?
Indo-Bangla Pharmaceuticals' current Receivables Turnover is 0.00. Based on the distribution chart, Indo-Bangla Pharmaceuticals ranks #999999 out of 947 companies in the Drug Manufacturers industry, which is in the bottom quartile relative to peers. Overall, Indo-Bangla Pharmaceuticals has a GF Score™ of 32/100, reflecting its overall financial health beyond just this single metric.
How does Indo-Bangla Pharmaceuticals' Receivables Turnover compare to ?
According to the Drug Manufacturers industry distribution chart, Indo-Bangla Pharmaceuticals ranks #999999 out of 947 companies for Receivables Turnover. This places Indo-Bangla Pharmaceuticals in the lower half of its industry. The industry median Receivables Turnover is 5.07. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Receivables Turnover for a Drug Manufacturers company?
The median Receivables Turnover among Drug Manufacturers companies is 5.07, based on 947 companies in the industry. Companies in the top quartile (top 25%) have a Receivables Turnover significantly above this median, while those in the bottom quartile fall well below. However, Receivables Turnover should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Receivables Turnover mean?
A high Receivables Turnover can signal that a stock is expensive relative to its fundamentals. The accounts receivables turnover ratio measures the number of times a company collects its average accounts receivable balance. It is calculated as Revenue divided by Average Accounts Receivable. View historical data on Indo-Bangla Pharmaceuticals and its competitors. For the Drug Manufacturers industry, the median Receivables Turnover is 5.07 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Indo-Bangla Pharmaceuticals's current Receivables Turnover is 0.00. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Indo-Bangla Pharmaceuticals stock overvalued right now?
Indo-Bangla Pharmaceuticals (DHA:IBP) has a current Receivables Turnover of 0.00. The current Receivables Turnover is 0.00. Indo-Bangla Pharmaceuticals' overall GF Score™ is 32/100. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Receivables Turnover calculated?
Receivables Turnover is calculated from a company's financial statements. For Indo-Bangla Pharmaceuticals (DHA:IBP), the current Receivables Turnover is 0.00 as of . 20. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Indo-Bangla Pharmaceuticals Ltd is engaged in the manufacturing, marketing, and distribution of generic pharmaceutical products. The products of the company include human drugs dosages form such as tablets, capsules, syrup, oral saline, and suspension. The products of the company are sold in the domestic market.
32GF Score
Get the complete analysis for DHA:IBP
Receivables Turnover is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
DHA:IBP has been successfully added to your 